Cargando…

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL

Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Erman, Ana, Ignjatović, Marija, Leskovšek, Katja, Miceska, Simona, Lampreht Tratar, Urša, Bošnjak, Maša, Kloboves Prevodnik, Veronika, Čemažar, Maja, Kandolf Sekulovič, Lidija, Avguštin, Gorazd, Ocvirk, Janja, Mesti, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377397/
https://www.ncbi.nlm.nih.gov/pubmed/37509655
http://dx.doi.org/10.3390/biomedicines11072016
_version_ 1785079507703562240
author Erman, Ana
Ignjatović, Marija
Leskovšek, Katja
Miceska, Simona
Lampreht Tratar, Urša
Bošnjak, Maša
Kloboves Prevodnik, Veronika
Čemažar, Maja
Kandolf Sekulovič, Lidija
Avguštin, Gorazd
Ocvirk, Janja
Mesti, Tanja
author_facet Erman, Ana
Ignjatović, Marija
Leskovšek, Katja
Miceska, Simona
Lampreht Tratar, Urša
Bošnjak, Maša
Kloboves Prevodnik, Veronika
Čemažar, Maja
Kandolf Sekulovič, Lidija
Avguštin, Gorazd
Ocvirk, Janja
Mesti, Tanja
author_sort Erman, Ana
collection PubMed
description Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression of PD-L1 and IFNγ from the primary tumor, stool and body fluids as potential biomarkers for response. Methods: Patients treated with immune checkpoint inhibitors as a first line treatment for metastatic melanoma are recruted to this prospective study. Stool samples are submitted before the start of treatment, at the 12th (+/−2) week and 28th (+/−2) week, and at the occurrence of event (suspected disease progression/hyperprogression, immune-related adverse event (irAE), deterioration). Peripheral venous blood samples are taken additionally at the same time points for cytologic and molecular tests. Histological material from the tumor tissue is obtained before the start of immunotherapy treatment. Primary objectives are to determine whether the human gastrointestinal microbiome (bacterial and viral) and the exosomal mRNA expression of PD-L1 and IFNγ and its dynamics predicts the response to treatment with PD-1 and CTLA-4 inhibitors and its association with the occurrence of irAE. The response is evaluated radiologically with imaging methods in accordance with the irRECIST criteria. Conclusions: This is the first study to combine and investigate multiple potential predictive and prognostic biomarkers and their dynamics in first line ICI in metastatic melanoma patients.
format Online
Article
Text
id pubmed-10377397
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103773972023-07-29 The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL Erman, Ana Ignjatović, Marija Leskovšek, Katja Miceska, Simona Lampreht Tratar, Urša Bošnjak, Maša Kloboves Prevodnik, Veronika Čemažar, Maja Kandolf Sekulovič, Lidija Avguštin, Gorazd Ocvirk, Janja Mesti, Tanja Biomedicines Study Protocol Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression of PD-L1 and IFNγ from the primary tumor, stool and body fluids as potential biomarkers for response. Methods: Patients treated with immune checkpoint inhibitors as a first line treatment for metastatic melanoma are recruted to this prospective study. Stool samples are submitted before the start of treatment, at the 12th (+/−2) week and 28th (+/−2) week, and at the occurrence of event (suspected disease progression/hyperprogression, immune-related adverse event (irAE), deterioration). Peripheral venous blood samples are taken additionally at the same time points for cytologic and molecular tests. Histological material from the tumor tissue is obtained before the start of immunotherapy treatment. Primary objectives are to determine whether the human gastrointestinal microbiome (bacterial and viral) and the exosomal mRNA expression of PD-L1 and IFNγ and its dynamics predicts the response to treatment with PD-1 and CTLA-4 inhibitors and its association with the occurrence of irAE. The response is evaluated radiologically with imaging methods in accordance with the irRECIST criteria. Conclusions: This is the first study to combine and investigate multiple potential predictive and prognostic biomarkers and their dynamics in first line ICI in metastatic melanoma patients. MDPI 2023-07-18 /pmc/articles/PMC10377397/ /pubmed/37509655 http://dx.doi.org/10.3390/biomedicines11072016 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Study Protocol
Erman, Ana
Ignjatović, Marija
Leskovšek, Katja
Miceska, Simona
Lampreht Tratar, Urša
Bošnjak, Maša
Kloboves Prevodnik, Veronika
Čemažar, Maja
Kandolf Sekulovič, Lidija
Avguštin, Gorazd
Ocvirk, Janja
Mesti, Tanja
The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title_full The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title_fullStr The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title_full_unstemmed The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title_short The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
title_sort prognostic and predictive value of human gastrointestinal microbiome and exosomal mrna expression of pd-l1 and ifnγ for immune checkpoint inhibitors response in metastatic melanoma patients: protocol trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377397/
https://www.ncbi.nlm.nih.gov/pubmed/37509655
http://dx.doi.org/10.3390/biomedicines11072016
work_keys_str_mv AT ermanana theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT ignjatovicmarija theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT leskovsekkatja theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT miceskasimona theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT lamprehttratarursa theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT bosnjakmasa theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT klobovesprevodnikveronika theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT cemazarmaja theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT kandolfsekuloviclidija theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT avgustingorazd theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT ocvirkjanja theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT mestitanja theprognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT ermanana prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT ignjatovicmarija prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT leskovsekkatja prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT miceskasimona prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT lamprehttratarursa prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT bosnjakmasa prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT klobovesprevodnikveronika prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT cemazarmaja prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT kandolfsekuloviclidija prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT avgustingorazd prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT ocvirkjanja prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial
AT mestitanja prognosticandpredictivevalueofhumangastrointestinalmicrobiomeandexosomalmrnaexpressionofpdl1andifngforimmunecheckpointinhibitorsresponseinmetastaticmelanomapatientsprotocoltrial